5. What do we do now? Implications for the clinical practice.

The primary objective of this supplement is to provide eye care practitioners (ECPs) with the latest research and experience on topics related to contact lens use and patient eye health. This section examines a variety of topics, including the challenges of keeping abreast of the scientific literature, recognizing data that are borne from well-designed studies, and keys to their implementation in clinical practice. Insights are also provided on how eye care is practiced in Asia, where regulations and patient perceptions result in care that is delivered much differently than in North America and Europe.

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.

Background: Besifloxacin ophthalmic suspension 0.6% is a new topical fluoroquinolone for the treatment of bacterial conjunctivitis. Besifloxacin has potent in vitro activity against a broad spectrum of ocular pathogens, including drug-resistant strains.